Syndax Pharmaceuticals (SNDX) Competitors $13.66 +0.03 (+0.22%) (As of 09:39 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SNDX vs. ACLX, ADMA, APLS, RARE, BHVN, IMVT, RNA, SRRK, OGN, and PTCTShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Arcellx (ACLX), ADMA Biologics (ADMA), Apellis Pharmaceuticals (APLS), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Immunovant (IMVT), Avidity Biosciences (RNA), Scholar Rock (SRRK), Organon & Co. (OGN), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Arcellx ADMA Biologics Apellis Pharmaceuticals Ultragenyx Pharmaceutical Biohaven Immunovant Avidity Biosciences Scholar Rock Organon & Co. PTC Therapeutics Arcellx (NASDAQ:ACLX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends. Do analysts rate ACLX or SNDX? Arcellx currently has a consensus target price of $105.93, indicating a potential upside of 29.14%. Syndax Pharmaceuticals has a consensus target price of $37.64, indicating a potential upside of 176.13%. Given Syndax Pharmaceuticals' higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Does the media refer more to ACLX or SNDX? In the previous week, Arcellx had 6 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for Arcellx and 4 mentions for Syndax Pharmaceuticals. Arcellx's average media sentiment score of 0.78 beat Syndax Pharmaceuticals' score of 0.76 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, ACLX or SNDX? Arcellx has higher revenue and earnings than Syndax Pharmaceuticals. Arcellx is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$155.82M28.47-$70.69M-$0.71-115.53Syndax Pharmaceuticals$16M72.71-$209.36M-$3.63-3.75 Does the MarketBeat Community favor ACLX or SNDX? Syndax Pharmaceuticals received 319 more outperform votes than Arcellx when rated by MarketBeat users. However, 82.93% of users gave Arcellx an outperform vote while only 65.48% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArcellxOutperform Votes6882.93% Underperform Votes1417.07%Syndax PharmaceuticalsOutperform Votes38765.48% Underperform Votes20434.52% Which has more risk and volatility, ACLX or SNDX? Arcellx has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Is ACLX or SNDX more profitable? Syndax Pharmaceuticals has a net margin of 0.00% compared to Arcellx's net margin of -25.94%. Arcellx's return on equity of -8.28% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-25.94% -8.28% -5.21% Syndax Pharmaceuticals N/A -64.34%-57.72% Do insiders & institutionals hold more shares of ACLX or SNDX? 96.0% of Arcellx shares are held by institutional investors. 6.2% of Arcellx shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryArcellx beats Syndax Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Ad DTIForced out of retirement by these trades You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedMake sure to check out Gamma Pockets HERE while it’s still widely available Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.16B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-3.7510.75135.1917.53Price / Sales72.71287.861,232.15140.37Price / CashN/A56.6540.6537.95Price / Book2.095.394.884.92Net Income-$209.36M$152.04M$118.97M$225.78M7 Day Performance-4.22%-4.32%15.41%-1.58%1 Month Performance-15.39%2.80%15.47%6.67%1 Year Performance-30.71%17.30%34.58%22.48% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals3.9667 of 5 stars$13.66+0.2%$37.64+175.5%-34.4%$1.17B$16M-3.76110ACLXArcellx3.0444 of 5 stars$84.46+0.8%$105.93+25.4%+60.5%$4.57B$155.82M-118.03130ADMAADMA Biologics3.8605 of 5 stars$19.07+2.6%$21.25+11.4%+343.6%$4.51B$382.81M68.32530Short Interest ↓APLSApellis Pharmaceuticals4.721 of 5 stars$34.12+2.8%$49.94+46.4%-34.5%$4.24B$396.59M-16.35702Analyst DowngradeShort Interest ↓Positive NewsRAREUltragenyx Pharmaceutical4.5688 of 5 stars$45.93+0.3%$87.46+90.4%-2.2%$4.24B$434.25M-7.081,276BHVNBiohaven3.8327 of 5 stars$41.67+8.3%$63.00+51.2%+0.3%$4.21B$462.51M-4.11239Analyst ForecastIMVTImmunovant1.4499 of 5 stars$27.54+4.8%$47.89+73.9%-34.7%$4.04BN/A-11.84120RNAAvidity Biosciences2.5121 of 5 stars$33.82+4.1%$63.60+88.1%+278.5%$4.04B$10.12M-11.28190Gap DownSRRKScholar Rock3.9591 of 5 stars$42.99+2.4%$40.43-6.0%+130.0%$4.02B$33.19M-18.35140Positive NewsOGNOrganon & Co.4.851 of 5 stars$14.74-3.7%$21.33+44.7%+12.9%$3.80B$6.26B2.9110,000PTCTPTC Therapeutics3.9956 of 5 stars$47.76+3.0%$54.08+13.2%+65.6%$3.68B$900.66M-8.041,410Positive News Related Companies and Tools Related Companies ACLX Alternatives ADMA Alternatives APLS Alternatives RARE Alternatives BHVN Alternatives IMVT Alternatives RNA Alternatives SRRK Alternatives OGN Alternatives PTCT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNDX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts